Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).

被引：0

作者：

Jacobus, Susanna ^{[1
]}

Kumar, Shaji ^{[2
]}

Callander, Natalie Scott ^{[3
]}

Abonour, Rafat ^{[4
]}

Fonseca, Rafael ^{[5
]}

Siegel, David ^{[6
]}

Greipp, Philip ^{[2
]}

Rajkumar, S. Vincent ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Wisconsin, Madison, WI USA

[4] Indiana Univ Canc, Indianapolis, IN USA

[5] Mayo Clin, Scottsdale, AZ USA

[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：613 / 614

页数：2

共 50 条

[21] A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.
Usmani, Saad Zafar
Schjesvold, Fredrik
Rocafiguera, Albert Oriol
Karlin, Lionel
Rifkin, Robert M.
Yimer, Habte Aragaw
LeBlanc, Richard
Takezako, Naoki
McCroskey, Robert Donald
Suzuki, Kenshi
Cavo, Michele
Facon, Thierry
Jagannath, Sundar
Lonial, Sagar
Ghori, Razi
Farooqui, Mohammed Z. H.
Liao, Jason
Marinello, Patricia
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] UPDATED OVERALL SURVIVAL ANALYSIS OF THE FIRST STUDY: CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS MELPHALAN, PREDNISONE, AND THALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Facon, T.
Dimopoulos, M. A.
Hulin, C.
Benboubker, L.
Belch, A.
Ludwig, H.
Pinto, A.
Attal, M.
Cavo, M.
Moreau, P.
Schots, R.
Meuleman, N.
Weisel, K.
Tiab, M.
Lee, J. J.
Butler, A.
Marek, J.
Chen, G.
Ervin-Haynes, A.
Fermand, J. P.
HAEMATOLOGICA, 2015, 100 : 3 - 3
[23] Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1AOO): Results of a phase III trial coordinated by the eastern cooperative oncology group.
Rajkumar, SV
Blood, E
Vesole, DH
Shepard, R
Greipp, PR
BLOOD, 2004, 104 (11) : 63A - 63A
[24] A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1AOO): Atrial coordinated by the Eastern Cooperative Oncology Group.
Rajkumar, SV
Blood, E
Vesole, DH
Shepard, R
Greipp, PR
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 560S - 560S
[25] Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Delforge, Michel
Minuk, Leonard
Eisenmann, Jean-Claude
Arnulf, Bertrand
Canepa, Letizia
Fragasso, Alberto
Leyvraz, Serge
Langer, Christian
Ezaydi, Yousef
Vogl, Dan T.
Giraldo-Castellano, Pilar
Yoon, Sung-Soo
Zarnitsky, Charles
Escoffre-Barbe, Martine
Lemieux, Bernard
Song, Kevin
Bahlis, Nizar Jacques
Guo, Shien
Monzini, Mara Silva
Ervin-Haynes, Annette
Houck, Vanessa
Facon, Thierry
HAEMATOLOGICA, 2015, 100 (06) : 826 - 833
[26] A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial
Facon, Thierry
Hulin, Cyrille
Dimopoulos, Meletios A.
Belch, Andrew
Meuleman, Nathalie
Mohty, Mohamad
Chen, Wen-Ming
Kim, Kihyun
Zamagni, Elena
Rodriguez-Otero, Paula
Renwick, William
Rose, Christian
Tempescul, Adrian
Palumbo, Antonio
Guo, Shien
Sturniolo, Michael
Ervin-Haynes, Annette
Fermand, Jean-Paul
BLOOD, 2015, 126 (23)
[27] Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
Gentile, Massimo
Magarotto, Valeria
Offidani, Massimo
Musto, Pellegrino
Bringhen, Sara
Petrucci, Maria Teresa
Gay, Francesca
Larocca, Alessandra
Uccello, Giuseppina
Petrungaro, Annamaria
Vigna, Ernesto
Greco, Rosa
Recchia, Anna Grazia
Tripepi, Giovanni
Ria, Roberto
Di Raimondo, Francesco
Palumbo, Antonio
Morabito, Fortunato
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (03) : 244 - 250
[28] Lenalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM): Results of a randomized, phase III trial
Lentzsch, Suzanne
Miao, Susanna
Schecter, Jordan Mark
Griffith, Kent A.
Normolle, Daniel Paul
Mapara, Markus Y.
Redner, Robert L.
Villanueva, Nicolas
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[29] Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura
Oriol, Albert
Rios Tamayo, Rafael
Jesus Blanchard, María
Jarque, Isidro
Bargay, Joan
Hernandez, Miguel-Teodoro
Maria Moraleda, Jose
Carrillo-Cruz, Estrella
Sureda, Anna
Martinez-Lopez, Joaquin
Krsnik, Isabel
Gonzalez Garcia, Esther
Casado, Felipe
Marti, Josep M.
Encinas, Cristina
De Arriba, Felipe
Palomera, Luis
Sampol, Antonia
Gonzalez-Montes, Yolanda
Cabezudo, Elena
Mateos, Maria-Victoria
San-Miguel, Jesus
Jose Lahuerta, Juan
Blade Creixenti, Joan
BLOOD, 2021, 138
[30] OVERALL SURVIVAL OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: ADJUSTING FOR CROSSOVER IN THE MM-003 TRIAL FOR POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE
Morgan, G.
San Miguel, J. F.
Dhanasiri, S.
Lee, D.
Palumbo, A.
Facon, T.
Zaki, M.
Yu, X.
Sternas, L.
Jacques, C.
Weisel, K.
Offner, F.
Dimopoulos, M.
HAEMATOLOGICA, 2014, 99 : 365 - 366

← 1 2 3 4 5 →